1. Size the walk-away cost, not the return — adoption is gated by the size of the failure
The repeatable method
- For any new capital good, ask what a buyer loses if the project fails outright, in absolute dollars. That number, not the projected IRR, determines who is willing to be the first customer.
- Compare it to the incumbent alternative's failure cost. A technology whose downside is an order of magnitude smaller can be adopted by buyers who could never have written the incumbent cheque.
- Recognise the corollary: shrinking the failure cost expands the number of possible buyers even if unit economics are worse. Market size can grow while cost per unit of output rises.
- Then check whether the smaller cheque still clears a corporate approval threshold without board-level, decade-long commitment. That is where the adoption actually accelerates.
Here: large reactors "take a decade or more to build, and cost over $10 billion each"; microreactors are far less powerful, "but buyers don't have to take the risk of a massive capital project. Even if a microreactor project fails, the cost of walking away will be in the millions, not the billions." Segra's Arthur Hyde puts it as a risk-management sentence, not a return one: "At a minimum, this reactor is not making me bankrupt."
Watch for
- Quoted per-unit capital cost and delivery lead time; whether orders come from corporate budgets rather than project-finance structures; the first non-anchor buyer's cheque size relative to its annual capex.
2. Find the sector's binary technical milestone and sort the field by it
The repeatable method
- In any pre-revenue hardware sector, identify the one event that converts "a design" into "a working machine." It should be objective, externally witnessed, and pass/fail — not a funding round or a partnership.
- Build the list of who has passed it and who has not. Ignore valuation while doing this; the two lists rarely match.
- Treat passing as retiring a category of risk, not all risk — name explicitly what remains (licensing, cost, customers).
- Look for the mismatches: a company with a rich valuation and no milestone is a story; one with the milestone and a modest valuation is where the work should go.
Here: the milestone is criticality — under a DOE program, "a small handful of firms… built reactors able to reach 'criticality,' equivalent to getting a car to successfully start running when you turn the key." Passed: Valar, Antares, Westinghouse, Aalo. Not named: NNE, NKLR, FISN, Radiant. And the honest boundary is stated: "the reactors didn't generate electricity."
Watch for
- The next milestone up the ladder (first electricity to a load, then a commercial operating licence — none of these firms has one yet); DOE program cohort announcements; NRC licensing-application dockets and acceptance dates.
3. Screen commercial viability on the overhead that does not scale with size
The repeatable method
- List every cost that is fixed per installation rather than per unit of output — security, permitting, site selection, licensing, staffing, insurance.
- Divide that fixed bill by the small unit's output. If the ratio is punitive, "smaller" is not cheaper in service, whatever the capital cost says.
- Identify buyers who already pay those fixed costs for another reason. They are the only economically rational first customers, and their adoption proves nothing about the wider market.
- Then look for the design that attacks the ratio — usually by aggregating many units behind one perimeter, one permit, one crew — and make that the criterion for who survives commercially.
Here: "Nuclear reactors need to be guarded 24 hours a day… manageable for a large reactor," but "hiring armed guards around the clock in a remote location for a small amount of power wouldn't be cost-effective," plus permitting and site-selection — Hyde: "it becomes almost impossible to have that economically make sense." The buyer who already pays the bill is the one buying first: bases "that already have 24/7 protection." The design answer is Valar Atomics — "at least 30 small or midsize reactors at one site."
Watch for
- Announced site plans with unit counts per site (the aggregation signal); NRC staffing/security rule changes for small reactors, which would directly move the screen; any commercial order at a site without existing security.
4. Separate what an anchor order proves from what it merely funds
The repeatable method
- Read the anchor customer's stated objective. If it is capability or resilience rather than cost, the order validates that the machine works — never that it is economic.
- Divide the contract value by the number of firms and the number of units. Ask directly whether the arithmetic supports the private valuations that the news is being used to justify.
- Treat the anchor order as (a) non-dilutive funding, (b) a public reference installation, (c) a regulatory relationship — three real assets, none of which is product-market fit.
- Write down the specific event that would prove commercial demand, and wait for it before paying a commercial multiple.
Here: the Army's objective is stated by Secretary Dan Driscoll as "energy resilience necessary to project combat power globally, without relying on potentially vulnerable external grids" — resilience, not price. Salzman does the arithmetic himself: "The Army contracts are nice, but they're not going to justify multibillion-dollar valuations for all these firms" — $2.2B across five firms and 20+ reactors, against private marks of $1.9B–$6B. Radiant says the quiet part: it hopes the project will "prove that its technology works and open up commercial opportunities."
Watch for
- The first fully commercial (non-government) order and its site type; whether a data-center operator signs rather than merely announces an MOU; the September 2028 first-switch-on date slipping, which resets everything downstream.
5. When private marks exceed public comps in the same niche, arbitrage the gap or take it as a warning
The repeatable method
- Put the private valuations and the public market caps of the same technology on one line. The usual relationship is a liquidity discount for private; an inversion is information.
- Test the two obvious explanations: the private names are genuinely further ahead (check against the milestone list from insight #2), or the private marks are stale/structured (preference stacks, ratchets) and not comparable to a common-share market cap.
- If the public names carry equivalent technical progress at a fraction of the value, that is the tradable expression of the theme.
- If they do not, treat the inversion as evidence that the public market is pricing the sector more soberly than the private one — and size accordingly.
Here: private — Valar $6B (on $1B raised this month), Antares $2.1B ($370M), Radiant $1.9B (>$500M raised). Public — NNE $1B, NKLR $625M, FISN ~$400M, described as "modest." Run the milestone test and the inversion partly resolves: the criticality cohort is private (Valar, Antares, Westinghouse, Aalo), the public trio is not on that list.
Watch for
- Pitchbook/round terms (preference and ratchets, which inflate headline marks); any of the private names going public and where it prices; the public names announcing criticality, which would close the technical gap.
6. Weight the specialist who states the bear case and still commits capital
The repeatable method
- Prefer sources who articulate the strongest objection to their own sector — it demonstrates the analysis is real rather than promotional.
- Then look at where they invest anyway. The gap between their general skepticism and their specific positions is the actual screen they are running, expressed as revealed preference.
- Reverse-engineer the criterion: what do the names they own have that the ones they dismiss do not?
- Apply that criterion to the rest of the field yourself — including to names they have not commented on.
Here: Hyde supplies every bear point in the article — security costs, permitting, "almost impossible to have that economically make sense" — and then: "Segra has invested in Valar Atomics and Terra Innovatum." Reverse-engineered criterion: a design that aggregates units at one site (30+ for Valar) and produces process heat as well as electricity, "expand[ing] the markets it can serve." That is a screen you can run on NNE, FISN and the privates yourself.
Watch for
- Segra's disclosed positions changing; other nuclear-dedicated funds converging on the same two criteria; company presentations that start emphasising units-per-site and industrial heat offtake, which would show the market has adopted the screen.
7. Check whether the incumbent has quietly bought an option on the disruptive format
The repeatable method
- Before underwriting a startup on the premise that incumbents are asleep, search the incumbent's own disclosures for a program in the same format.
- Weigh the capability the incumbent holds that the entrants cannot buy — usually regulatory experience, manufacturing, or an installed service base — and ask whether that is the binding constraint in this sector.
- Where the incumbent is private or embedded, identify the listed vehicle that carries the exposure, and treat it as a cheaper, lower-variance way to own the theme.
- Discount the entrants' terminal value by the probability the incumbent simply arrives late and wins on licensing.
Here: "Westinghouse owns the most advanced large-reactor design on the market today, but has also been testing its own microreactor," plans to deploy some at Army bases, and is in the criticality cohort. None of the entrants has a commercial operating licence — the exact competence Westinghouse has most of. The listed vehicles are CCJ (49%) and Brookfield, which folds this into the July 31 pre-IPO thesis rather than starting a new one.
Watch for
- Westinghouse microreactor disclosures inside Cameco's quarterly filings; the Westinghouse IPO prospectus (which would itemise the program); whether the Army's later awards shift toward the incumbent as designs move to licensing.
8. State the single unresolved question and refuse to pay for it until it resolves
The repeatable method
- Reduce the whole thesis to one open question. If you cannot, you have not finished the analysis.
- Define the observable that answers it — a named buyer, a signed contract, a site type — and the date by which it should appear.
- Until then, own the exposures that pay whether or not it resolves (the incumbent, the diversified supplier, the fuel), and keep the pure bets small.
- Note that a credible institutional critic is not noise: it is a marker of where the argument is genuinely unsettled.
Here: the closing line is the question — "The military is ready to deploy microreactors. For the industry to succeed, it will have to convince other buyers too." The institutional dissent is named: Third Way argues microreactors are "an inefficient method of meeting America's growing electricity needs." Exposures that pay either way: BWXT (existing revenue plus the order) and CCJ (fuel plus the incumbent's option).
Watch for
- A commercial buyer — a hyperscaler, an industrial site — signing for a microreactor at a location without pre-existing security; DOE/NRC cost-benefit assessments answering Third Way; the first electricity actually delivered to a load.